Propylthiouracil

Thyroid Hormone Synthesis Inhibitor — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Propylthiouracil is an ofp drug in the Thyroid Hormone Synthesis Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1947. Its mechanism of action is classified as Thyroid Hormone Synthesis Inhibitors. DrugCentral lists 5 molecular targets, including TAS2R38, MPO and LPO. Recorded indications include Hyperthyroidism and Thyrotoxic crisis.

• Approval status: ofp (first approved 1947 by the FDA).
• Drug class: Thyroid Hormone Synthesis Inhibitor.
• Mechanism of action: Thyroid Hormone Synthesis Inhibitors.
• Molecular targets: TAS2R38, MPO, LPO and TPO (5 listed in DrugCentral).
• Indications: Hyperthyroidism and Thyrotoxic crisis.
• ATC code: H03BA02 (Thiouracils).
• Molecular formula: C7H10N2OS; molecular weight 170.23 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Hyperthyroidism
• Thyrotoxic crisis

Contraindications (12)

• Agranulocytosis
• Bone marrow depression
• Drug-induced hepatitis
• Hyperbilirubinemia
• Hypothyroidism
• Interstitial pneumonia
• Leukopenia
• Liver function tests abnormal
• Necrotizing vasculitis
• Pancytopenia
• Pregnancy, function
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Thyroid Hormone Synthesis Inhibitors
• Established pharmacologic class: Thyroid Hormone Synthesis Inhibitor

Molecular targets (5)

Target	Gene	Action	Activity
Taste receptor type 2 member 38	TAS2R38	unknown	EC50 5.70
Myeloperoxidase	MPO	unknown	IC50 5.55
Lactoperoxidase	LPO	unknown	IC50 5.12
Thyroid peroxidase	TPO	inhibitor	IC50 5.06
Type I iodothyronine deiodinase	DIO1	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1947-07-28	FDA	—	DAVA PHARMS INC

ATC classification

ATC code	Therapeutic hierarchy
H03BA02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › THYROID THERAPY › ANTITHYROID PREPARATIONS › Thiouracils

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Anti-neutrophil cytoplasmic antibody positive vasculitis	398.0
Foetal exposure during pregnancy	250.0
Hyperthyroidism	206.1
Thyrotoxic crisis	179.8
Antineutrophil cytoplasmic antibody positive	144.3
Exposure during pregnancy	139.0
Agranulocytosis	112.7
Cardiogenic shock	106.6
Acute hepatic failure	104.9
Goitre congenital	101.2
Premature baby	97.7
Vasculitis	91.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Propylthiouracil is on its molecule page.

• Molecular formula: C₇H₁₀N₂OS
• Molecular weight: 170.23 g/mol
• CAS number: 51-52-5
• InChIKey: KNAHARQHSZJURB-UHFFFAOYSA-N
• PubChem CID: 657298

CCCC1=CC(=O)NC(=S)N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Propylthiouracil used for?

DrugCentral lists the following indications for Propylthiouracil: Hyperthyroidism and Thyrotoxic crisis.

How does Propylthiouracil work?

Propylthiouracil is classified as Thyroid Hormone Synthesis Inhibitors; its molecular targets in DrugCentral include TAS2R38, MPO, LPO and TPO (inhibitor).

When was Propylthiouracil first approved?

Propylthiouracil was first approved by the FDA in 1947.

What drug class does Propylthiouracil belong to?

Propylthiouracil is in the Thyroid Hormone Synthesis Inhibitor class.

What is the chemical formula of Propylthiouracil?

Propylthiouracil has the molecular formula C7H10N2OS and a molecular weight of 170.23 g/mol.

Sources

• DrugCentral drug card 2308 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1518 — compound record and bioactivity
• PubChem CID 657298 — chemical identifiers
• DrugBank DB00550 — drug record
• FDA UNII 721M9407IY — substance identity
• DailyMed: FDA labels for Propylthiouracil — current prescribing information (label search)
• UniProt P59533 (TAS2R38) — target protein
• UniProt P05164 (MPO) — target protein
• UniProt P22079 (LPO) — target protein
• UniProt P07202 (TPO) — target protein
• UniProt P49895 (DIO1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.